Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax Plus Azacitidine vs Standard Chemotherapy in Newly Diagnosed NPM1-Mutated AML
NCT05904106Phase 2Recruiting
- Sponsor
- Technische Universität Dresden
- Start
- Apr 2024
- Primary completion
- Sep 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of venetoclax in acute myeloid leukemia (AML), sponsored by Technische Universität Dresden. Started Apr 2024; status: recruiting.
02
Drugs
venetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05904106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05904106.